EG-301
- Generic Name
- EG-301
Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to dAMD
Phase 2
Not yet recruiting
- Conditions
- Non-Exudative (dry) Age-related Macular Degeneration (dAMD)
- Interventions
- Dietary Supplement: AREDS2 supplements
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Evergreen Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05170048
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath